Live Breaking News & Updates on Day One Lab Readiness|Page 1

Stay updated with breaking news from Day one lab readiness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

John Gilardi , Robert Reitze , Jean Pascal Viola , Thomas Theuringer , Phoebe Loh , Exchange Commission , Amgen Inc , Lab Readiness , Drug Administration , Day One Lab Readiness , Us Securities Exchange , One Lab Readiness , Frankfurt Prime Standard , Senior Vice President , Diagnostics Business , Darryl Sleep , Global Medical , Precision Medicine , Molecular Diagnostics , Applied Testing , Exchange Act , ஜீன் பாஸ்கல் வயல , ஃபோப் லோ , பரிமாற்றம் தரகு , மகேன் இன்க் , ஆய்வகம் ரெடிநெஸ் ,

QIAGEN N.V.: QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer

(0)
The therascreen
KRAS RGQ PCR Kit receives U.S. regulatory approval from FDA for expanded scope to include use in guiding treatment with the newly approved therapy LUMAKRAS
TM (sotorasib) from Amgen
KRAS G12C mutation in NSCLC
Test will be available under QIAGEN s Day One Lab Readiness program
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the
therascreen
KRAS RGQ PCR Kit (
therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRAS ....

John Gilardi , Robert Reitze , Jean Pascal Viola , Thomas Theuringer , Phoebe Loh , Exchange Commission , Amgen Inc , Lab Readiness , Drug Administration , Day One Lab Readiness , Us Securities Exchange , One Lab Readiness , Frankfurt Prime Standard , Senior Vice President , Diagnostics Business , Darryl Sleep , Global Medical , Precision Medicine , Molecular Diagnostics , Applied Testing , Exchange Act , ஜீன் பாஸ்கல் வயல , ஃபோப் லோ , பரிமாற்றம் தரகு , மகேன் இன்க் , ஆய்வகம் ரெடிநெஸ் ,